Singular Focus, Purpose-Built Solutions: Your Partner in Life Science Insurance
Berkley Life Sciences is solely dedicated to providing premiere insurance coverage for today’s top life sciences companies.
Life Sciences Insurance Protecting Tomorrow’s Innovations
Comprehensive. Customized. Multinational. We provide property and casualty insurance products and services tailored to life sciences businesses globally. Our approach is collaborative, with underwriting, in-house claims, and risk management working in tandem to provide a complete and specialized insurance solution.
In-House Claims
From the start of the underwriting process, our in-house claims team is a true partner in your insurance experience. With extensive life science products liability claim and litigation expertise, our claims team collaborates with insureds, brokers, and our defense counsel to actively lead claims to just resolution.
The Power of Berkley
Berkley Life Sciences is one of the 55+ (re)insurance businesses worldwide that comprise the Berkley brand. Berkley is one of America’s largest commercial lines property casualty insurance providers, operating worldwide within two segments of the P&C insurance business: Insurance and Reinsurance & Monoline Excess. Each business offers expertise within an industry, product, or region.
Berkley Life Sciences is a member of W. R. Berkley Corporation, a Fortune 500 company listed on the New York Stock Exchange and is part of the S&P 500. W. R. Berkley Corporation’s insurance company subsidiaries are rated A+ (Superior), Financial Size Category XV by A.M. Best Company and A+ (Strong) by Standard & Poor’s.
Berkley’s competitive advantage lies in its long-term strategy of decentralized operations. This structure provides each Berkley business the agility of a small business—the ability to identify and respond quickly and effectively to changing market conditions and local customer needs. It provides our Berkley businesses with the strength and resources of a Fortune 500 organization as well as the financial accountability and incentives to attract and retain the highest-caliber professionals.
The Latest in Life Science
PFAS in Medical & Life Sciences Products: A Regulatory & Litigation Update
In 2023, Berkley Life Sciences published a blog post titled PFAS “Forever Chemicals” in Medical and Life Sciences Products – Who Should Be Worried?. At that time, most per- and polyfluoroalkyl substances (PFAS) litigation to date focused on lawsuits against PFAS manufacturers, alleging personal injury from PFAS exposure. Since then, PFAS litigation has evolved, and both the U.S. Food and Drug Administration (FDA) and European Chemicals Agency (ECHA) have issued updates, warranting a fresh look at this topic.
Beyond Terminal: How Montana Is Redefining Right to Try Laws
Montana's Right to Try laws - Senate Bill 422 (2023) and Senate Bill 535 (2025) allow any patient, not just those with terminal illness, to access experimental treatments that have passed Phase 1 safety trials. Clinics offering these treatments must be licensed and contribute to patient support funds. Patients must provide informed consent before treatment.
How 3D Printing is Revolutionizing Pediatric Prosthetics
Traditional pediatric prosthetics present significant challenges for families and clinicians alike. These devices are often expensive, difficult to customize, and inaccessible to children in remote or low-income areas. Because children grow quickly, prosthetics require frequent replacements and adjustments, adding financial and logistical strain.